Lilly targets infectious-disease prevention with three same-day vaccine acquisitions

Eli Lilly is seeking its next growth platform in infectious-disease prevention, announcing agreements to acquire three companies in a coordinated push that the market has framed as a “same-day” shift away from its obesity-driven spotlight. The deals were announced May 26, 2026, in three separate acquisition agreements, and covered a combined purchase value of up to $3.83 billion in cash, contingent on upfront and later milestones.

The largest piece is Curevo Inc., whose lead candidate is amezosvatein, an adjuvanted subunit shingles vaccine designed for adults. Lilly said amezosvatein is engineered with a “next-generation” synthetic adjuvant intended to improve tolerability, and it reported that in a Phase 2 head-to-head study against the current standard, the vaccine matched immune responses while reducing certain side effects, including fatigue, chills, and injection-site pain by more than half. Lilly also linked shingles prevention to downstream risks it says have been increasingly associated with the infection, including elevated stroke risk and lower dementia risk among vaccinated people.

Lilly will also acquire LimmaTech Biologics AG to build a bacterial vaccine portfolio aimed at targets including Staphylococcus aureus, Neisseria gonorrhoeae, and Chlamydia trachomatis. In the company’s description, LimmaTech’s approach is built to generate broad, durable immune responses against complex bacterial targets by focusing on toxins and superantigens that drive disease. Its lead program, LTB-SA7, is in Phase 1 development as a vaccine against S. aureus, a leading cause of surgical-site infection, and Lilly said the company’s preclinical pipeline includes additional pathogens associated with long-term consequences, including infertility-related risks.

The third acquisition, Vaccine Company, is positioned around a manufacturing-light vaccine technology called In Vivo Nanoparticle (IVN). In Lilly’s account, the platform aims to display antigens in the body in a way that elicits durable, virus-like-particle-associated immune responses, while avoiding the manufacturing burden of traditional VLPs, or virus-like particles. Lilly said the company’s lead program applies the IVN approach to Epstein-Barr virus (EBV), with a five-antigen candidate described as “Phase 1-ready,” and it cited growing evidence linking EBV to multiple sclerosis and several malignancies as a reason a prophylactic vaccine could have broader impact than preventing acute infectious mononucleosis.

Taken together, Lilly said the acquisitions reflect a strategy to prevent disease at its source rather than treat later consequences, and it pointed to scientific links between common infections and diseases that may emerge years after initial infection, as well as rising antimicrobial resistance that, in Lilly’s view, makes vaccines increasingly important for bacterial targets. The company has previously made GLP-1-based obesity and diabetes therapies central to its growth narrative, and the new investments add vaccine development as a second pillar aimed at long-term risk reduction, not just short-term symptom control.

What Lilly did not disclose in its public announcement are the exact upfront amounts for each deal, its timeline for closing the transactions, or any sales or market-size forecasts tied to the programs. The company also emphasized that the candidates are investigational and that closing is subject to customary conditions, including completion of the Hart-Scott-Rodino antitrust waiting period. With amezosvatein already in Phase 2 and LimmaTech’s lead program in Phase 1, investors will likely focus next on interim clinical readouts, progress in Phase 1 readiness for the EBV candidate, and whether Lilly can translate these technologies into durable late-stage clinical results.